We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Factors Likely to Influence AB InBev's (BUD) Earnings in Q1
Read MoreHide Full Article
Anheuser-Busch InBev SA/NV (BUD - Free Report) , also known as AB InBev, is slated to release first-quarter 2021 results on May 6. The leading alcohol beverage company is likely to register year-over-year top and bottom-line growth when it reports first-quarter 2021 results. The Zacks Consensus Estimate for AB InBev’s first-quarter bottom line is pegged at earnings of 48 cents per share, suggesting significant growth from a loss of 42 cents reported in the year-ago quarter. The consensus estimate has been unchanged in the past seven days.
For first-quarter revenues, the consensus mark is pegged at $11.49 billion, suggesting 4.5% growth from the prior-year reported figure.
In the last reported quarter, the company delivered a negative earnings surprise of 14.3%. Moreover, its earnings missed the Zacks Consensus Estimate by 22.8%, on average, in the trailing four quarters.
Key Factors to Note
AB InBev’s top line has been witnessing momentum, driven by a marked recovery in volume and revenue per hectoliter (hl). Despite the pandemic-led challenges, it reported better-than-expected revenue results as well as organic revenue growth in fourth-quarter 2020. Strength in the off-premise channel and premium brands as well as investment in B2B platforms, e-commerce channels and digital marketing in the past few months have been key growth drivers. Moreover, the company has been witnessing an improving volume trend, which has been aiding organic top-line performance. The persistence of the factors is likely to have aided the first-quarter performance.
Moreover, the company’s fundamental strength as well as continued resilience in the global beer category is expected to have aided sales performance in the to-be-reported quarter.
Additionally, AB InBev’s commercial strategy has been driving strong revenue performance in North America, including gains in the United States and Canada, even though the effects of the second wave of the COVID-19 outbreak have resulted in renewed restriction. In the fourth quarter of 2020, the continued execution of the commercial strategy resulted in market share gains of 40 basis points (bps) in the United States, which is expected to have continued in the first quarter. Further, the strong performance of its above core brands, including Michelob ULTRA, Bud Light Seltzer and Corona, is expected to have been key drivers in the quarter under review.
Also, the company’s investment in B2B platforms, e-commerce channels and digital marketing has accelerated in the past few months, which is expected to have boosted top and bottom-line growth in the to-be-reported quarter. The company’s first-quarter performance is expected to have gained from the continued investments in its portfolio as well as rapidly growing its digital platform, including BEES and Ze Delivery.
However, the company has been witnessing cost headwinds, driven by higher cost of sales, SG&A expenses and other costs, which is likely to have impacted margins in the first quarter. Supply-chain adjustments to meet the evolving demand and operational deleveraging resulting from the impacts of COVID-19 on volumes have been hurting cost of sales. This is expected to have weighed on gross margin performance in the quarter under review.
Moreover, EBITDA margin is expected to have been under pressure due to the adverse channel and packaging mix along with currency and commodity headwinds.
Zacks Model
Our proven model doesn’t conclusively predict earnings beat for AB InBev this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
AB InBev has a Zacks Rank #3 and Earnings ESP of 0.00%.
Stocks Poised to Beat Earnings Estimates
Here are some companies that you may want to consider as our model shows that these have the right combination of elements to deliver an earnings beat.
Nomad Foods Limited (NOMD - Free Report) currently has an Earnings ESP of +0.73% and a Zacks Rank #3.
Tyson Foods, Inc. (TSN - Free Report) has an Earnings ESP of +16.03% and a Zacks Rank #3 at present.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Factors Likely to Influence AB InBev's (BUD) Earnings in Q1
Anheuser-Busch InBev SA/NV (BUD - Free Report) , also known as AB InBev, is slated to release first-quarter 2021 results on May 6. The leading alcohol beverage company is likely to register year-over-year top and bottom-line growth when it reports first-quarter 2021 results. The Zacks Consensus Estimate for AB InBev’s first-quarter bottom line is pegged at earnings of 48 cents per share, suggesting significant growth from a loss of 42 cents reported in the year-ago quarter. The consensus estimate has been unchanged in the past seven days.
For first-quarter revenues, the consensus mark is pegged at $11.49 billion, suggesting 4.5% growth from the prior-year reported figure.
In the last reported quarter, the company delivered a negative earnings surprise of 14.3%. Moreover, its earnings missed the Zacks Consensus Estimate by 22.8%, on average, in the trailing four quarters.
Key Factors to Note
AB InBev’s top line has been witnessing momentum, driven by a marked recovery in volume and revenue per hectoliter (hl). Despite the pandemic-led challenges, it reported better-than-expected revenue results as well as organic revenue growth in fourth-quarter 2020. Strength in the off-premise channel and premium brands as well as investment in B2B platforms, e-commerce channels and digital marketing in the past few months have been key growth drivers. Moreover, the company has been witnessing an improving volume trend, which has been aiding organic top-line performance. The persistence of the factors is likely to have aided the first-quarter performance.
Moreover, the company’s fundamental strength as well as continued resilience in the global beer category is expected to have aided sales performance in the to-be-reported quarter.
AnheuserBusch InBev SANV Price and EPS Surprise
AnheuserBusch InBev SANV price-eps-surprise | AnheuserBusch InBev SANV Quote
Additionally, AB InBev’s commercial strategy has been driving strong revenue performance in North America, including gains in the United States and Canada, even though the effects of the second wave of the COVID-19 outbreak have resulted in renewed restriction. In the fourth quarter of 2020, the continued execution of the commercial strategy resulted in market share gains of 40 basis points (bps) in the United States, which is expected to have continued in the first quarter. Further, the strong performance of its above core brands, including Michelob ULTRA, Bud Light Seltzer and Corona, is expected to have been key drivers in the quarter under review.
Also, the company’s investment in B2B platforms, e-commerce channels and digital marketing has accelerated in the past few months, which is expected to have boosted top and bottom-line growth in the to-be-reported quarter. The company’s first-quarter performance is expected to have gained from the continued investments in its portfolio as well as rapidly growing its digital platform, including BEES and Ze Delivery.
However, the company has been witnessing cost headwinds, driven by higher cost of sales, SG&A expenses and other costs, which is likely to have impacted margins in the first quarter. Supply-chain adjustments to meet the evolving demand and operational deleveraging resulting from the impacts of COVID-19 on volumes have been hurting cost of sales. This is expected to have weighed on gross margin performance in the quarter under review.
Moreover, EBITDA margin is expected to have been under pressure due to the adverse channel and packaging mix along with currency and commodity headwinds.
Zacks Model
Our proven model doesn’t conclusively predict earnings beat for AB InBev this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
AB InBev has a Zacks Rank #3 and Earnings ESP of 0.00%.
Stocks Poised to Beat Earnings Estimates
Here are some companies that you may want to consider as our model shows that these have the right combination of elements to deliver an earnings beat.
Monster Beverage Corporation (MNST - Free Report) presently has an Earnings ESP of +0.41% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nomad Foods Limited (NOMD - Free Report) currently has an Earnings ESP of +0.73% and a Zacks Rank #3.
Tyson Foods, Inc. (TSN - Free Report) has an Earnings ESP of +16.03% and a Zacks Rank #3 at present.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>